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ABSTRACT
Introduction: The progressive nature of type 2
diabetes necessitates treatment intensification.
This often involves intensification with oral
antidiabetic drugs (OADs) initially, followed by
other agents, such as glucagon-like peptide-1
receptor agonists (GLP-1RAs), with the majority
of patients eventually requiring insulin therapy.
Therefore, this trial aimed to investigate the
efficacy of IDegLira (combination of insulin
degludec and liraglutide) in controlling
glycemia in adults with type 2 diabetes who
were inadequately controlled on a GLP-1RA and
OADs.
Methods: In this 26-week open-label phase 3b
trial, patients on maximum-dose GLP-1RA
therapy (liraglutide once daily or exenatide
twice daily) with metformin alone or with
pioglitazone and/or sulfonylurea were
randomized 2:1 to IDegLira once daily
(n = 292) or to unchanged GLP-1RA therapy
(n = 146), continuing OADs at the pre-trial
dose.
Results: After 26 weeks, HbA1c reductions were
superior with IDegLira versus unchanged
GLP-1RA; estimated treatment difference
-0.94% (-10.3 mmol/mol), p\0.001. Mean
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HbA1c reduced from 7.8% to 6.4% (61.5 to
46.9 mmol/mol) with IDegLira and from 7.7 to
7.4% (60.8 to 57.1 mmol/mol) with unchanged
GLP-1RA. With IDegLira, 75% and 63% of
patients achieved HbA1c \7% and B6.5%,
compared with 36% and 23% on unchanged
GLP-1RA, respectively. Fasting plasma glucose
and 9-point self-monitored blood glucose
profiles improved significantly more with
IDegLira versus unchanged GLP-1RA. The
mean change in weight was ?2.0 kg with
IDegLira, versus -0.8 kg with unchanged
GLP-1RA. Rates of confirmed hypoglycemia
were low, but higher with IDegLira versus
unchanged GLP-1RA. The safety profile of
IDegLira was consistent with previous
findings; both treatments were well tolerated
and the rate of nausea was low in both groups.
IDegLira improved patient-reported outcomes
versus unchanged GLP-1RA.
Conclusions: IDegLira provided superior
glycemic control versus unchanged GLP-1RA
and represents an efficacious intensification
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INTRODUCTION
Due to the progressive nature of type 2 diabetes,
current therapies, including glucagon-like
peptide-1 receptor agonists (GLP-1RAs), usually
do not provide sustained glycemic control, so
treatment intensification is necessary in many
patients [1, 2]. Insulin remains the most
efficacious glucose-lowering therapy, and is
typically initiated when patients are unable to
achieve glycemic control with lifestyle changes,
oral antidiabetic drugs (OADs), and GLP-1RAs
[2, 3].GLP-1RAs canoffer significant reductions in
HbA1c with a low risk of hypoglycemia and
significant weight loss [4]. Several studies have
demonstrated the clinical benefits of using basal
insulin and GLP-1RAs together [5–9], and their
co-use is supported by treatment guidelines [2].
Thus, intensificationwithbasal insulin is seen as a
natural progression for patients whose blood
glucose is not controlled by aGLP-1RA andOADs.
Insulin degludec/liraglutide (IDegLira) is the
first combination of a basal insulin (insulin
degludec) and a GLP-1RA (liraglutide). The
complementary modes of action of the two
molecules can help to control both fasting
plasma glucose (FPG) and postprandial glucose
(PPG). IDegLira is available as a single
once-daily injection that can be taken at any
time of day, but preferably at the same time
each day [10]. IDegLira is administered and
titrated in a treat-to-target manner as dose steps,
with each dose step containing 1 unit (U) of
insulin degludec and 0.036 mg of liraglutide, up
to a maximum of 50 dose steps (50 U insulin
degludec and 1.8 mg liraglutide) daily [10].
The DUAL phase 3 clinical trial program
investigated the efficacy and safety of IDegLira
in patients with type 2 diabetes. DUAL I and its
26-week extension showed that IDegLira
provided clinical advantages and improved
glycemic control compared with its
monocomponents given alone in insulin-naı¨ve
patients [11, 12]. DUAL II investigated the
contribution of liraglutide in IDegLira in
insulin-experienced patients, with patients on
IDegLira achieving superior glycemic control
versus those on insulin degludec (which was
capped at 50 U per day) [13]. DUAL IV
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investigated the efficacy and safety of IDegLira
in insulin-naı¨ve patients inadequately
controlled with sulfonylurea with or without
metformin, where it demonstrated superior
glycemic control versus placebo [14]. DUAL V
compared IDegLira with the uptitration of
insulin glargine 100 units/mL in patients who
were inadequately controlled on 20–50 U of
insulin glargine 100 units/mL, with IDegLira
resulting in superior HbA1c, a lower rate of
hypoglycemia, and weight loss versus insulin
glargine 100 units/mL [15].
The primary objective of the DUAL III
clinical trial was to confirm the superiority of
IDegLira compared with continuing on
unchanged GLP-1RA therapy in controlling
glycemia in insulin-naı¨ve adult patients with
type 2 diabetes who were inadequately
controlled with the maximum approved or
tolerated dose of a GLP-1RA and OADs. The
secondary objective of the trial was to compare
the general efficacy and safety of IDegLira with
unchanged GLP-1RA.
METHODS
Trial Design and Participants
This was a 26-week, multi-center, randomized,
open-label, two-group parallel, treat-to-target
trial conducted at 81 sites in five countries
(Australia, France, Hungary, Slovakia, and the
United States) between August 2012 and March
2014. The trial was registered at clinicaltrials.gov
(NCT01676116), and was conducted in
accordance with Declaration of Helsinki and
ICH Good Clinical Practice [16, 17]. Informed
consent was obtained from all patients before
they were included in the trial.
Insulin-naı¨ve patients with type 2 diabetes
were enrolled if they were inadequately
controlled with a GLP-1RA and OADs
(metformin alone or in combination with
pioglitazone and/or sulfonylurea). Pre-trial
patients were treated with the maximum dose
(according to the local label) or the maximum
tolerated dose of either liraglutide once daily or
exenatide twice daily, and OADs at stable dose
for at least 90 days before screening. Patients
were included if they were C18 years of age, had
an HbA1c of 7.0–9.0% (53–75 mmol/mol, both
inclusive), and a body mass index (BMI) B40 kg/
m2. Patients were excluded if they had used any
OADs except for metformin, pioglitazone, and
sulfonylurea within 90 days prior to screening.
Full inclusion and exclusion criteria are
provided in the Table S1 in the Electronic
supplementary material, ESM.
Randomization and Masking
Patients were stratified according to pre-trial
type of GLP-1RA and randomized 2:1 to
IDegLira or to continue on unchanged
GLP-1RA therapy using an interactive voice/
web response system. IDegLira was dosed once
daily and could be administered at any time of
the day, but preferably at the same time each
day. Those on unchanged GLP-1RA continued
on their pre-trial dosing regimen. Treatment
assignment was masked for the safety
committee and independent adjudication
committee throughout the trial. No
randomization codes were broken before
database lock.
Procedures
IDegLira (100 units/mL insulin degludec and
3.6 mg/mL liraglutide in a 3 mL pre-filled
PDS290 pen-injector, Novo Nordisk, Bagsværd,
Denmark) was injected subcutaneously. The
starting dose of IDegLira was 16 dose steps
(16 U insulin degludec and 0.6 mg liraglutide).
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Adjustment of IDegLira dose was performed
twice weekly based on the three preceding
pre-breakfast self-monitored blood glucose
(SMBG) measurements. The IDegLira dose was
titrated to an FPG target of 4.0–5.0 mmol/L
(72–90 mg/dL) (Table S2 in the ESM). IDegLira
could be titrated up to a maximum of 50 dose
steps (50 U insulin degludec and 1.8 mg
liraglutide).
Patients randomized to the unchanged
GLP-1RA treatment continued their pre-trial
treatment schedule without making any
changes. Liraglutide (Victoza) was
administered once daily using a 6.0 mg/mL
solution provided in a 3-mL prefilled pen.
Exenatide (Byetta) was administered twice
daily using a 250 lg/mL solution provided in
1.2-mL or 2.4-mL prefilled pens. All previous
OADs (metformin, pioglitazone, sulfonylurea)
were continued at pre-trial doses in both groups
unless there was a safety concern. OAD dose
reduction was allowed for safety reasons
(including hypoglycemic events) based on the
judgment of the investigator.
At the screening visit, each patient was
provided with a blood glucose monitoring meter
in order to perform regular SMBG; this was used
according to the manufacturer’s instructions.
Outcomes
The primary endpoint was change in HbA1c
from baseline after 26 weeks of treatment. Key
secondary efficacy endpoints included
responders for HbA1c [predefined targets of
\7% (53 mmol/mol) and B6.5%
(48 mmol/mol)] after 26 weeks of treatment,
change from baseline in body weight,
laboratory-measured FPG, and nine-point
SMBG profile.
Safety variables included the number of
treatment-emergent adverse events and
episodes of confirmed hypoglycemia.
Confirmed hypoglycemia was defined as
plasma glucose B3.1 mmol/L (B56 mg/dL) or
severe hypoglycemia which required third-party
assistance. Nocturnal confirmed hypoglycemia
was defined as confirmed hypoglycemia
occurring between 00:01 and 05:59, inclusive.
Other safety endpoints included clinical
evaluation (physical examination, fundoscopy,
blood pressure, ECG, and pulse) and laboratory
variables (including lipid profile, amylase,
lipase, and calcitonin).
Patient-reported outcomes (PROs) were
measured using the treatment-related impact
measure—diabetes (TRIM-D) and diabetes
treatment satisfaction questionnaire status
(DTSQs) [18–20]. The TRIM-D questionnaire
was used to measure the treatment-related
impact of the diabetes medication, whereby a
higher TRIM-D total score indicated a better
health state [18, 19]. The DTSQs consisted of a
questionnaire consisting of eight items; items 2
and 3 were perceived frequency of
hyperglycemia and hypoglycemia, respectively,
and were analyzed individually in the data
analysis. A higher score for these items
reflected a higher perceived frequency of
hyperglycemia or hypoglycemia. The
treatment satisfaction score was based on the
sum of the remaining six items of the
questionnaire. A higher score in the DTSQs
treatment satisfaction scale total indicates
higher patient satisfaction with treatment [20].
Statistics
The trial was powered to the primary objective
of demonstrating superiority using a two-sided
t test of size 5%, under the assumptions of a
0.4% treatment difference with a 1.2% standard
deviation. From these assumptions, a total of
429 patients were randomized 2:1 to IDegLira
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and unchanged GLP-1RA in order to obtain a
nominal power of 90%.
The full analysis set (FAS) included all
randomized subjects, and was used to analyze
HbA1c, FPG, SMBG, hypoglycemia, and body
weight. The safety endpoints were summarized
using the safety analysis set (SAS), which
included all randomized subjects receiving at
least one dose of the investigational product.
Missing values were imputed using last
observation carried forward (LOCF). The
primary endpoint was also analyzed for the
per protocol analysis set (all subjects in the FAS
who fulfilled the inclusion criteria, had not
violated any of the exclusion criteria, had HbA1c
values from screening, randomization and after
12 weeks of treatment, and were exposed to the
trial product for at least 12 weeks), completers
analysis set (all randomized subjects who
completed the trial), and using a repeated
measurement analysis (missing data were
imputed using a mixed-model repeated
measurement technique rather than utilizing
LOCF, in order to evaluate the sensitivity of
using LOCF).
Change in HbA1c was analyzed using an
analysis of covariance (ANCOVA) on the FAS.
Treatment, pre-trial GLP-1RA, and region
(Australia, Europe, or North America) were
included as fixed effects with baseline HbA1c
as covariate. IDegLira was to be considered
superior if the upper bound of the 95%
confidence interval (CI) for the treatment
difference was below 0.
Other continuous variables (mean of the
nine-point SMBG profile, FPG, and body
weight) were also analyzed by ANCOVA.
Attainment of HbA1c target \7.0%
(53 mmol/mol) and B6.5% (48 mmol/mol) was
analyzed using a logistic regression model on
the FAS population using LOCF, with
treatment, pre-trial GLP-1 RA, and region as
fixed factors and baseline HbA1c value as
covariate.
Hypoglycemia was analyzed using a negative
binomial regression model based on the FAS
population, with treatment, pre-trial GLP-1RA,
and region included as fixed factors and the
logarithm of the time period in which an
episode was considered treatment emergent as
offset.
TRIM-D and DTSQs questionnaires were
completed at baseline, visit 14, and the end of
the trial. Change from baseline score in each
subdomain as well as the total score after
26 weeks of treatment were analyzed for the
FAS population by ANCOVA, with treatment,
pre-trial GLP-1 RA, and region as fixed effects
and baseline value as covariate.
RESULTS
Of the 704 patients screened, 438 were
randomized to receive trial product; 292 to
IDegLira and 146 to unchanged GLP-1RA
(Figure S1 in the ESM). Pre-trial, and in the
unchanged GLP-1RA group, 79.5% of patients
were treated with liraglutide and 20.5% with
exenatide twice daily. A total of 94.5% of those
randomized to IDegLira completed the trial
versus 80.1% of those who were randomized
to unchanged GLP-1RA. The baseline and
demographic characteristics were similar for
the treatment groups (Table 1). Patients
continued with their pretrial OADs, with
similar proportions of patients on one, two, or
three OADs in each treatment group (Table 1).
After 26 weeks, the mean IDegLira dose was 43
dose steps, equating to 43 U of insulin degludec
and 1.5 mg of liraglutide.
Over the 26-week trial, the observed mean
[standard deviation (SD)] HbA1c decreased from
a baseline of 7.8% (0.6) [61.5 mmol/mol (6.2)]
to 6.4% (0.8) [46.9 mmol/mol (9.0)] with
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IDegLira and from 7.7% (0.5) [60.8 mmol/mol
(6.7)] to 7.4% (1.0) [57.1 mmol/mol (10.9)] with
unchanged GLP-1RA. The mean reductions in
HbA1c were 1.3% (0.8) [14.5 mmol/mol (9.3)]
and 0.3% (0.9) [3.8 mmol/mol (10.0)] with
IDegLira and unchanged GLP-1RA, respectively
(Fig. 1a). IDegLira was superior to unchanged
GLP-1RA, with an estimated treatment
difference (ETD) of -0.94% (-1.11; -0.78)95%
CI, [-10.3 mmol/mol (-12.2; –8.5)95% CI],
p\0.001. Furthermore, the robustness of the
primary analysis was substantiated by three
sensitivity analyses (the repeated measurement
analysis, per protocol analysis, and completer
analysis), all of which confirmed the superiority
of IDegLira (data not shown).
Overall, 75% of patients on IDegLira
achieved the HbA1c target of \7.0%
(53 mmol/mol) versus 36% on unchanged
GLP-1RA therapy; estimated odds ratio (EOR)
of 6.84 [4.28; 10.94]95% CI, p\0.001. Similarly,
significantly more patients on IDegLira (63%)
versus those on unchanged GLP-1RA (23%)
attained the HbA1c target B6.5%
(48 mmol/mol); EOR: 7.53 (4.58; 12.38)95% CI,
p\0.001 (Fig. 1b).
Table 1 Baseline characteristics
Characteristic IDegLira Unchanged GLP-1RA
Full analysis set (FAS), n 292 146
Female/male, % 47.6/52.4 51.4/48.6
Race: white/black/Asian/American Indian (or Alaska native)/other, % 92.1/5.1/2.1/0.3/0.3 89.7/8.2/1.4/0.0/0.7
Ethnicity: Hispanic or Latin American, % 8.9 10.3
Age, years 58.3 ± 9.9 58.4 ± 8.8
Weight, kg 95.6 ± 16.6 95.5 ± 17.3
BMI, kg/m2 32.9 ± 4.4 33.0 ± 4.1
Duration of diabetes, years 10.4 ± 5.8 10.4 ± 5.8
HbA1c, % 7.8 ± 0.6 7.7 ± 0.6
mmol/mola 61.5 ± 6.2 60.8 ± 6.7
FPG, mmol/L 9.0 ± 2.1 9.4 ± 2.3
mg/dL 161.7 ± 38.2 169.1 ± 41.7
Pretrial OADs, %
Metformin 74.3 74.0
Metformin ? sulfonylurea 20.9 21.9
Metformin ? pioglitazone 2.4 2.7
Metformin ? sulfonylurea ? pioglitazone 2.4 1.4
Duration of treatment with GLP-1RA prior to randomization, days 468.1 ± 616.0 498.6 ± 525.1
Values are the mean ± SD unless otherwise stated
GLP-1RA glucagon-like peptide-1 receptor agonist, IDegLira insulin degludec/liraglutide combination, OAD oral
antidiabetic drug, SD standard deviation
a Calculated not measured
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During the trial, there was a statistically
significantly greater improvement in
laboratory-measured FPG from baseline with
IDegLira versus unchanged GLP-1RA, resulting
in end-of-trial mean (SD) values of 6.0 mmol/L
(1.6) and 8.8 mmol/L (2.7), respectively. The
Fig. 1 a Glycemic efﬁcacy HbA1c over time. Mean
observed values with error bars (standard error of the
mean) based on FAS and LOCF imputed data. ETD is
from ANCOVA analysis, and change in HbA1c (D) values
are observed; both are based on FAS and LOCF imputed
data. Dotted lines represent ADA/EASD and AACE
HbA1c targets of \7.0% and B6.5%, respectively.
b Patients achieving the HbA1c target. Treatment com-
parisons are from a logistic regression model based on FAS
and LOCF imputed data. c FPG over time. Mean observed
values with error bars (standard error of the mean) based
on FAS and LOCF imputed data. ETD is from
ANCOVA analysis, and change in FPG (D) values are
observed; both are based on FAS and LOCF imputed data.
d Mean nine-point SMBG proﬁle at weeks 0 and 26.
*p\0.001 (post hoc analysis). Mean values are based on
FAS, with missing proﬁles imputed using LOCF; SMBG
was assessed with a glucose meter as plasma-equivalent
values of capillary whole blood glucose. ANCOVA analysis
of covariance, EOR estimated odds ratio, EOT end of trial,
FAS full analysis set, FPG fasting plasma glucose,
GLP-1RA glucagon-like peptide-1 receptor agonist, IDe-
gLira insulin degludec/liraglutide combination, LOCF last
observation carried forward, SMBG self-monitored blood
glucose
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mean (SD) reductions in FPG were 2.98 mmol/L
(2.28) with IDegLira and 0.60 mmol/L (2.74)
with unchanged GLP-1RA, ETD: -2.64 mmol/L
(-3.03; -2.25)95% CI, p\0.001 (Fig. 1c).
After 26 weeks, the mean nine-point SMBG
profile had decreased with both treatments
versus baseline. The end-of-trial mean of the
nine-point SMBG profile was statistically
significantly lower with IDegLira versus
unchanged GLP-1RA, with an ETD of
-1.78 mmol/L (-2.13; -1.43)95% CI, p\0.001.
At all nine time points, measured SMBG values
were statistically significantly lower with
IDegLira versus unchanged GLP-1 RA (Fig. 1d,
post hoc analysis). Importantly, glucose control
did not deteriorate during the first 4 weeks with
IDegLira after transfer from the pre-trial
GLP-1RA dose (Fig. 2) [1.2 or 1.8 mg liraglutide
(mean daily dose at baseline 1.7 mg) or 5 or
10 lg exenatide twice daily (mean daily dose at
baseline 18.4 lg) maximum dose, depending on
local label or maximum tolerated dose] to the
IDegLira starting dose of 16 dose steps (16 U
insulin degludec and 0.6 mg liraglutide).
After 26 weeks, observed mean (SD) body
weight increased by 2.0 kg (3.9) from baseline
with IDegLira and decreased by 0.8 kg (3.0) with
unchanged GLP-1RA, corresponding to a
statistical significant ETD of 2.89 kg (2.17;
3.62)95% CI, p\0.001, in favor of unchanged
GLP-1RA (Fig. 3). Body weight was also
summarized according to whether patients
were treated with concomitant sulfonylurea
therapy. With IDegLira, the increase from
baseline in body weight was more pronounced
in the sulfonylurea-treated (3.3 kg) compared
with the non-sulfonylurea-treated patients
(1.6 kg). With unchanged GLP-1RA, the
change from baseline in body weight was -0.7
versus -0.8 kg in sulfonylurea-treated versus
non-sulfonylurea-treated patients, respectively.
With IDegLira there were 2.82 episodes of
confirmed hypoglycemia per patient-years of
exposure (PYE) versus 0.12 episodes per PYE
with unchanged GLP-1RA, corresponding to an
estimated rate ratio (ERR) of 25.36 (10.6;
Fig. 2 Glycemic control during the ﬁrst 4 weeks of the
trial. Values are the median with interquartile range, based
on FAS and with missing values imputed using LOCF.
FAS full analysis set, GLP-1RA glucagon-like peptide-1
receptor agonist, IDegLira insulin degludec/liraglutide
combination, LOCF last observation carried forward,
SMBG self-monitored blood glucose
Fig. 3 Body weight over time. Values are the mean with
error bars (standard error of the mean), based on FAS and
with missing values imputed using LOCF. Estimated
treatment differences are from an ANCOVA analysis.
ANCOVA analysis of covariance, FAS, full analysis set,
GLP-1RA glucagon-like peptide-1 receptor agonist, IDe-
gLira insulin degludec/liraglutide combination, LOCF last
observation carried forward
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60.5)95% CI, p\0.001 (Table 3 in the ESM). One
episode of severe hypoglycemia was reported in
the IDegLira group. The rate of nocturnal
confirmed hypoglycemia was statistically
significantly higher with IDegLira (0.454
episodes per PYE) compared with unchanged
GLP-1RA (0.015 episodes per PYE), ERR: 32.82
(4.13; 261.04)95% CI, p\0.001 (Table S3 in the
ESM). Hypoglycemic episodes were also
summarized according to whether patients
were receiving concomitant sulfonylurea
therapy. With IDegLira, the rate of confirmed
hypoglycemia was 6.34 events per PYE in
sulfonylurea-treated patients (n = 68) versus
1.75 events per PYE in
non-sulfonylurea-treated patients (n = 223).
With unchanged GLP-1RA, the event rate was
0.51 events per PYE in sulfonylurea-treated
patients (n = 34) and 0 events per PYE in
non-sulfonylurea-treated patients (n = 111)
(Table S4 in the ESM).
Overall, the proportions and rates of
treatment-emergent adverse events and serious
adverse events reported with IDegLira and
unchanged GLP-1RA were similar (Table 2).
The overall rates of adverse events were 410.1
events per 100 PYE with IDegLira and 364.3
events per 100 PYE with unchanged GLP-1RA;
the majority of these events were non-serious
and were evaluated as mild in severity by the
investigator. The most frequently reported
adverse events were nasopharyngitis, upper
respiratory tract infection, lipase increased,
headache and diarrhea. The rates of serious
adverse events were nine and five events per 100
PYE with IDegLira and unchanged GLP-1RA,
respectively (Table 2); none were reported as
possibly or probably related to the trial product.
No deaths were reported during the trial.
In three patients, adverse events resulted in
withdrawal: one with IDegLira (drug
hypersensitivity) and two with unchanged
GLP-1RA (abdominal discomfort and foot
fracture). Nausea occurred in 3.1% of patients
with IDegLira compared with 4.1% of patients
with unchanged GLP-1RA, with 7.8 versus 10.6
events per 100 PYE, respectively. Two major
adverse cardiovascular events (MACE) were sent
for adjudication; both were confirmed by the
external blinded event adjudication committee
as stroke and they occurred in the IDegLira
group. Seven potential neoplasms occurred
during the trial and were sent for adjudication.
Three of these were confirmed events of
neoplasm, two events with IDegLira, and one
with unchanged GLP-1RA. No medullary
thyroid carcinoma events were reported. An
additional event (lymphadenopathy) was also
sent for adjudication but was not confirmed as a
neoplasm. No pancreatitis or thyroid-related
adverse events occurred in either treatment
group.
Overall, the changes from baseline to week
26 in fasting lipid levels were small for both
treatment groups. At the end of the trial, total
cholesterol [estimated treatment ratio (ETR):
0.96 (0.93; 1.00)95% CI, p = 0.025], very low
density lipoprotein cholesterol [ETR: 0.90 (0.85;
0.96)95% CI, p\0.001], triglycerides [ETR: 0.88
(0.82; 0.94)95% CI, p\0.001], and free fatty acids
[ETR: 0.71 (0.65; 0.77)95% CI, p\0.001] were
statistically significantly lower with IDegLira
versus unchanged GLP-1RA. A decrease in lipase
activity from baseline to the end of the trial was
observed both with IDegLira (mean change
-1.0 units/L) and unchanged GLP-1RA (mean
change -1.8 units/L) (Table S5 in the ESM). An
increase in amylase activity was observed with
IDegLira (mean change 6.2 units/L) compared
with a decrease with unchanged GLP-1RA
(mean change -1.0 units/L) (Table S5 in the
ESM). No clinically relevant differences were
observed between treatment groups in mean
calcitonin levels, physical examination, or
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fundoscopy during the trial. There were no
statistically significant differences in systolic or
diastolic blood pressure between treatment
groups. After 26 weeks of treatment, there was
a statistically significant difference in mean
pulse between IDegLira and unchanged
GLP-1RA; ETD of 1.78 beats/min (0.22;
3.33)95% CI, p = 0.025.
The PRO scores improved with both
treatments from baseline to the end of the
trial, but to a greater extent with IDegLira. After
26 weeks of treatment with IDegLira, the
TRIM-D total score was statistically
significantly higher (indicating a better health
state/outcome) than with unchanged GLP-1 RA,
with an ETD of 5.0 units (2.9; 7.2)95% CI,
p\0.001 (Table S6 in the ESM). In both
treatment groups, all TRIM-D subdomain
scores and the total score increased
throughout the trial. In all subdomains, the
score increases were statistically significantly
higher with IDegLira versus unchanged
GLP-1RA (Table 6 in the ESM). After 26 weeks
of treatment, the DTSQs treatment satisfaction
score was statistically significantly higher with
IDegLira compared with unchanged GLP-1RA,
with an ETD of 2.0 units (1.1; 2.8)95% CI,
p\0.001. Hypoglycemia and hyperglycemia
were scored significantly higher and lower,
respectively, by patients treated with IDegLira
versus unchanged GLP-1RA, indicating a higher
perceived frequency of hypoglycemia and a
lower perceived frequency of hyperglycemia
with IDegLira (Table S6 in the ESM).
DISCUSSION
Due to the progressive nature of type 2 diabetes,
many patients need to intensify their treatment
in order to maintain glycemic control. A
commonly used approach is the initiation of a
GLP-1RA after one or more OADs fail to keep a
patient at the target HbA1c [21]. There are
currently several options for treatment
intensification in patients on a GLP-1RA, and
the addition of basal insulin is a recognized
option in the ADA/EASD guidelines [2].
Initiating basal insulin, and therefore the use
of IDegLira, is a natural progression in the
treatment of type 2 diabetes for those
uncontrolled on a GLP-1RA, where beta-cell
failure continues and endogenous insulin
secretion declines. This trial investigated the
efficacy and safety of IDegLira in patients with
type 2 diabetes uncontrolled on a GLP-1RA. It
demonstrates that when transferring from
Table 2 Adverse events
IDegLira Unchanged GLP-1RA
N (%) E R N (%) E R
Adverse events 191 65.6 578 410 92 63.4 240 364
Serious 9 3.1 12 9 3 2.1 3 5
Deaths 0 – – – 0 – – –
Severe 9 3.1 14 10 3 2.1 3 5
Probably related to investigational product 11 3.8 12 9 3 2.1 3 5
Related to device 0 – – – 0 – – –
% percentage of subjects, E number of events, N number of subjects with C1 event, R rate of events per 100 PYE, GLP-1RA
glucagon-like peptide-1 receptor agonist, IDegLira insulin degludec/liraglutide combination, PYE patient years of exposure
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maximum dose GLP-1RA to the IDegLira
starting dose of 16 dose steps, there was no
deterioration in blood glucose during the first
4 weeks of treatment. After 26 weeks, patients
on IDegLira achieved superior HbA1c, and had a
statistically significant reduction in FPG and
nine-point SMBG profile compared with those
who continued unchanged GLP-1RA therapy.
IDegLira also enabled significantly more
patients to reach the HbA1c targets of \7.0%
(53 mmol/mol) and B6.5% (48 mmol/mol).
Overall, the safety and tolerability profile of
IDegLira was consistent with previous findings
[11–14]. Initiation of IDegLira resulted in a
statistically significantly increase in weight
and a higher rate of hypoglycemia compared
with unchanged GLP-1RA, however, this is to be
expected following the introduction of insulin,
and has been observed in other trials of
insulin-naı¨ve patients [22–25]. Moreover, the
rate of hypoglycemia was low in both groups.
The concomitant use of sulfonylurea in *23%
of the patients in the IDegLira group may have
also contributed to the hypoglycemia and
weight gain. A post hoc summary showed that
hypoglycemia was more frequent in the
IDegLira plus sulfonylurea-treated patients
versus those on IDegLira without sulfonylurea;
this was also observed with unchanged
GLP-1RA. This is consistent with the results of
the DUAL IV clinical trial, where IDegLira was
investigated as an add-on to sulfonylurea
therapy and the rate of hypoglycemia was
higher [14] compared with other IDegLira
trials where concomitant sulfonylurea
treatment was not part of the background
OAD therapy [11, 13]. It is recognized that
insulin and sulfonylurea is a frequently used
combination [26]. According to the IDegLira
prescribing information, a reduction in the dose
of sulfonylurea should be considered when
IDegLira is added to sulfonylurea therapy [10],
whereas pre-trial doses were maintained during
this trial unless there was a safety concern. The
DUAL III trial had an FPG target of 4–5 mmol/L.
In DUAL IV, the FPG target was 4–6 mmol/L
(72–108 mg/dL) and the rate of confirmed
hypoglycemia with IDegLira plus sulfonylurea
was 3.5 versus 1.4 episodes per PYE with placebo
[14]. The ADA have recently raised their
glycemic target from 3.9–7.2 to 4.4–7.2 mmol/
L (70–130 to 80–130 mg/dL) [27]. Therefore, we
can speculate that lower rates of hypoglycemia
may be observed in real-life clinical practice
with IDegLira, where sulfonylurea doses would
be reduced and glycemic targets individualized
if the patient experienced hypoglycemia. The
frequency of nausea was low with both
treatments (occurring in 3.1% with IDegLira
and 4.1% with unchanged GLP-1RA); a low
frequency of nausea has also been observed
with IDegLira in other clinical trials [28].
Overall, IDegLira treatment had a positive
impact on PROs compared with unchanged
GLP-1RA. The change from baseline score for
TRIM-D in the IDegLira group was greater than
that in the unchanged GLP-1RA group. In the
DTSQ, patients treated with IDegLira reported
greater treatment satisfaction versus those on
unchanged GLP-1RA. According to the DTSQs,
patients on IDegLira perceived the frequency of
hypoglycemia to be higher and hyperglycemia to
be lower than inpatientsonunchangedGLP-1RA.
This is in line with the clinical results of the trial.
A limitation of this trial is that IDegLira was
compared to an unchanged pre-trial
comparator, and it would be interesting to
compare the initiation of IDegLira in patients
uncontrolled on a GLP-1RA with an active
comparator, e.g., basal insulin. Also, due to
the open-label nature of the trial, an
improvement in PRO may be expected in the
patients receiving the trial product compared
with those continuing their existing therapy.
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CONCLUSIONS
In conclusion, in patients inadequately
controlled on maximum dose GLP-1RA and
OADs, IDegLira resulted in a superior HbA1c
reduction and enabled patients to achieve a
lower FPG and nine-point SMBG profile
compared with patients continuing
unchanged GLP-1RA therapy. Patients treated
with IDegLira gained more weight and
experienced more hypoglycemia versus
unchanged GLP-1RA therapy; these results
are consistent with previous findings on
GLP-1RA intensification with
insulin-containing therapy. Treatment with
IDegLira resulted in a low rate of nausea and
improved PROs versus unchanged GLP-1RA.
IDegLira represents an efficacious and simple
approach to intensifying therapy in patients
uncontrolled on GLP-1RAs.
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